VRCA
Verrica Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$6.91
+0.30 (+4.54%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 35.21M | 35.73M | 38.70M |
| Net Income | 7.35M | 6.74M | 10.01M |
| EPS | — | — | — |
| Profit Margin | 20.9% | 18.9% | 25.9% |
| Rev Growth | +1.0% | +7.9% | +5.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 31.20M | 41.09M | 34.59M |
| Total Equity | 69.92M | 73.14M | 69.93M |
| D/E Ratio | 0.45 | 0.56 | 0.49 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 14.30M | 12.85M | 15.80M |
| Free Cash Flow | 5.70M | 8.80M | 7.67M |